Top

Published in:

01-07-2015 | Sepsis and ICU (L Napolitano, Section Editor)

Eliminating Infections in the ICU: CLABSI

Authors: Asad Latif, Muhammad Sohail Halim, Peter J. Pronovost

Published in: Current Infectious Disease Reports | Issue 7/2015

Abstract

Central line-associated bloodstream infections (CLABSI) are one of the leading causes of death in the USA and around the world. As a preventable healthcare-associated infection, they are associated with significant morbidity and excess costs to the healthcare system. Effective and long-term CLABSI prevention requires a multifaceted approach, involving evidence-based best practices coupled with effective implementation strategies. Currently recommended practices are supported by evidence and are simple, such as appropriate hand hygiene, use of full barrier precautions, avoidance of femoral lines, skin antisepsis, and removal of unnecessary lines. The most successful and sustained improvements in CLABSI rates further utilize an adaptive component to align provider behaviors with consistent and reliable use of evidence-based practices. Great success has been achieved in reducing CLABSI rates in the USA and elsewhere over the past decade, but more is needed. This article aims to review the initiatives undertaken to reduce CLABSI and summarizes the sentinel and recent literature regarding CLABSI and its prevention.

The Joint Commission. Preventing central line-associated bloodstream infections. 2012. at <http://www.jointcommission.org/topics/clabsi_toolkit.aspx> Accessed December 9, 2014.

Eliminating CLABSI: a national patient safety imperative. September 2011. Agency for Healthcare Research and Quality, Rockville, MD. http://www.ahrq.gov/professionals/quality-patient-safety/cusp/clabsi-update/index.html. Accessed December 9, 2014.

Centers for Disease Control (CDC). Public health focus: surveillance, prevention, and control of nosocomial infections. MMWR Morb Mortal Wkly Rep. 1992;41(42):783–7.

Umscheid CA et al. Estimating the proportion of healthcare-associated infections that are reasonably preventable and the related mortality and costs. Infect Control Hosp Epidemiol. 2011;32:101–14.PubMedCrossRef

Siempos II, Kopterides P, Tsangaris I, Dimopoulou I, Armaganidis AE. Impact of catheter-related bloodstream infections on the mortality of critically ill patients: a meta-analysis. Crit Care Med. 2009;37:2283–9.PubMedCrossRef

Wenzel RP, Edmond MB. The impact of hospital-acquired bloodstream infections. Emerg Infect Dis. 2001;7(2):174–7.PubMedCentralPubMedCrossRef

Centers for Disease Control and Prevention (CDC). Vital signs: central line-associated blood stream infections--United States, 2001, 2008, and 2009.MMWR Morb Mortal Wkly Rep. 2011;60(8):243-8.

Stevens V et al. Inpatient costs, mortality and 30-day re-admission in patients with central-line-associated bloodstream infections. Clin Microbiol Infect. 2014;20:O318–24.PubMedCrossRef

9.•

Herzer KR, Niessen L, Constenla DO, Ward WJ, Pronovost PJ. Cost-effectiveness of a quality improvement programme to reduce central line-associated bloodstream infections in intensive care units in the USA. BMJ Open. 2014;4:e006065. Decision tree analysis of an existing large-scale program on the economic costs related to central line associated blood stream infections from the perspective of US hospitals.PubMedCentralPubMedCrossRef

10.

Digiovine B, Chenoweth C, Watts C, Higgins M. The attributable mortality and costs of primary nosocomial bloodstream infections in the intensive care unit. Am J Respir Crit Care Med. 1999;160:976–81.PubMedCrossRef

11.

Rosenthal VD et al. International Nosocomial Infection Control Consortium (INICC) report, data summary of 36 countries, for 2004–2009. Am J Infect Control. 2012;40:396–407.PubMedCrossRef

12.

Goudie A, Dynan L, Brady PW, Rettiganti M. Attributable cost and length of stay for central line-associated bloodstream infections. Pediatrics. 2014;133:e1525–32.PubMedCentralPubMedCrossRef

13.

Edwards JR et al. National Healthcare Safety Network (NHSN) report: data summary for 2006 through 2008, issued December 2009. Am J Infect Control. 2009;37:783–805.PubMedCrossRef

14.

Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008;36:309–32.PubMedCrossRef

15.

O’Grady, Alexander, M, Burns LA, et al. CDC guidelines for the prevention of intravascular catheter-related infections. Centers for Disease Control and Prevention. at <http://www.cdc.gov/hicpac/BSI/BSI-guidelines-2011.html> Accessed December 9, 2014.

16.

Pratt RJ et al. epic2: national evidence-based guidelines for preventing healthcare-associated infections in NHS hospitals in England. J Hosp Infect. 2007;65 Suppl 1:S1–64.PubMedCrossRef

17.

Wolf H-H et al. Central venous catheter-related infections in hematology and oncology: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol. 2008;87:863–76.PubMedCrossRef

18.

Hoggard J, Saad T, Schon D, Vesely TM, Royer T. Guidelines for venous access in patients with chronic kidney disease: a position statement from the American society of diagnostic and interventional nephrology clinical practice committee and the association for vascular access. Semin Dial. 2008;21:186–91.PubMedCrossRef

19.

Marschall J et al. Strategies to prevent central line-associated bloodstream infections in acute care hospitals. Infect Control Hosp Epidemiol. 2008;29 Suppl 1:S22–30.PubMedCrossRef

20.

Pronovost P et al. An intervention to decrease catheter-related bloodstream infections in the ICU. N Engl J Med. 2006;355:2725–32.PubMedCrossRef

21.

Mermel LA. Prevention of intravascular catheter-related infections. Ann Intern Med. 2000;132:391–402.PubMedCrossRef

22.••

Berenholtz SM et al. Eliminating central line-associated bloodstream infections: a national patient safety imperative. Infect Control Hosp Epidemiol. 2014;35:56–62. A collaborative cohort study evaulating the impact of the national "On the CUSP: Stop BSI" program on central line associated bloodstream infection rates amongst participating ICUs across the US.PubMedCrossRef

23.

Allegranzi B, Pittet D. Role of hand hygiene in healthcare-associated infection prevention. J Hosp Infect. 2009;73:305–15.PubMedCrossRef

24.

Casewell M, Phillips I. Hands as route of transmission for Klebsiella species. Br Med J. 1977;2:1315–7.PubMedCentralPubMedCrossRef

25.

WHO guidelines on hand hygiene in healthcare. at <http://whqlibdoc.who.int/publications/2009/9789241597906_eng.pdf> Accessed December 9, 2014.

26.

Guideline for hand hygiene in health-care settings. at <http://www.cdc.gov/mmwr/PDF/rr/rr5116.pdf> Accessed December 9, 2014.

27.

Doebbeling BN et al. Comparative efficacy of alternative hand-washing agents in reducing nosocomial infections in intensive care units. N Engl J Med. 1992;327:88–93.PubMedCrossRef

28.

Walker JL et al. Hospital hand hygiene compliance improves with increased monitoring and immediate feedback. Am J Infect Control. 2014;42:1074–8.PubMedCrossRef

29.

MacDonald A, Dinah F, MacKenzie D, Wilson A. Performance feedback of hand hygiene, using alcohol gel as the skin decontaminant, reduces the number of inpatients newly affected by MRSA and antibiotic costs. J Hosp Infect. 2004;56:56–63.PubMedCrossRef

30.

Pittet D. Compliance with hand disinfection and its impact on hospital-acquired infections. J Hosp Infect. 2001;48(Suppl A):S40–6.PubMedCrossRef

31.

Pessoa-Silva CL et al. Reduction of health care associated infection risk in neonates by successful hand hygiene promotion. Pediatrics. 2007;120:e382–90.PubMedCrossRef

32.

Rosenthal VD, Guzman S, Safdar N. Reduction in nosocomial infection with improved hand hygiene in intensive care units of a tertiary care hospital in Argentina. Am J Infect Control. 2005;33:392–7.PubMedCrossRef

33.

Johnson L et al. A multifactorial action plan improves hand hygiene adherence and significantly reduces central line-associated bloodstream infections. Am J Infect Control. 2014;42:1146–51.PubMedCrossRef

34.

Macias JH et al. Chlorhexidine is a better antiseptic than povidone iodine and sodium hypochlorite because of its substantive effect. Am J Infect Control. 2013;41:634–7.PubMedCrossRef

35.

Paglialonga F et al. Reduction in catheter-related infections after switching from povidone-iodine to chlorhexidine for the exit-site care of tunneled central venous catheters in children on hemodialysis. Hemodial Int. 2014;18 Suppl 1:S13–8.PubMedCrossRef

36.

Yamamoto N et al. Efficacy of 1.0% chlorhexidine-gluconate ethanol compared with 10% povidone-iodine for long-term central venous catheter care in hematology departments: a prospective study. Am J Infect Control. 2014;42:574–6.PubMedCrossRef

37.

Chaiyakunapruk N, Veenstra DL, Lipsky BA, Saint S. Chlorhexidine compared with povidone-iodine solution for vascular catheter-site care: a meta-analysis. Ann Intern Med. 2002;136:792–801.PubMedCrossRef

38.

Vallés J et al. Prospective randomized trial of 3 antiseptic solutions for prevention of catheter colonization in an intensive care unit for adult patients. Infect Control Hosp Epidemiol. 2008;29:847–53.PubMedCrossRef

39.

Goudet V et al. Comparison of four skin preparation strategies to prevent catheter-related infection in intensive care unit (CLEAN trial): a study protocol for a randomized controlled trial. Trials. 2013;14:114.PubMedCentralPubMedCrossRef

40.

Chaiyakunapruk N, Veenstra DL, Lipsky BA, Sullivan SD, Saint S. Vascular catheter site care: the clinical and economic benefits of chlorhexidine gluconate compared with povidone iodine. Clin Infect Dis. 2003;37:764–71.PubMedCrossRef

41.

Noto MJ et al. Chlorhexidine bathing and health care-associated infections. JAMA. 2015;313:369–78.PubMedCrossRef

42.

Raad II et al. Prevention of central venous catheter-related infections by using maximal sterile barrier precautions during insertion. Infect Control Hosp Epidemiol. 1994;15:231–8.PubMedCrossRef

43.

O’Grady NP et al. Guidelines for the prevention of intravascular catheter-related infections. Clin infect Dis : Off Publ Infect Dis Soc Am. 2011;52:e162–93.CrossRef

44.

Pronovost P. Interventions to decrease catheter-related bloodstream infections in the ICU: the Keystone Intensive Care Unit Project. Am J Infect Control. 2008;36(10):S171.e1–5. doi: 10.1016/j.ajic.2008.10.008.

45.

Carrer S et al. Effect of different sterile barrier precautions and central venous catheter dressing on the skin colonization around the insertion site. Minerva Anestesiol. 2005;71:197–206.PubMed

46.

Tang H-J et al. The impact of central line insertion bundle on central line-associated bloodstream infection. BMC Infect Dis. 2014;14:356.PubMedCentralPubMedCrossRef

47.

Marik PE, Flemmer M, Harrison W. The risk of catheter-related bloodstream infection with femoral venous catheters as compared to subclavian and internal jugular venous catheters: a systematic review of the literature and meta-analysis. Crit Care Med. 2012;40:2479–85.PubMedCrossRef

48.

Weeks KR, Hsu Y-J, Yang T, Sawyer M, Marsteller JA. Influence of a multifaceted intervention on central line days in intensive care units: results of a national multisite study. Am J Infect Control. 2014;42:S197–202.PubMedCrossRef

49.

McLaws M-L, Berry G. Nonuniform risk of bloodstream infection with increasing central venous catheter-days. Infect Control Hosp Epidemiol. 2005;26:715–9.PubMedCrossRef

50.

Concannon C, van Wijngaarden E, Stevens V, Dumyati G. The effect of multiple concurrent central venous catheters on central line-associated bloodstream infections. Infect Control Hosp Epidemiol. 2014;35:1140–6.PubMedCrossRef

51.

Burdeu G, Currey J, Pilcher D. Idle central venous catheter-days pose infection risk for patients after discharge from intensive care. Am J Infect Control. 2014;42:453–5.PubMedCrossRef

52.

Fong KS et al. Intensity of vascular catheter use in critical care: impact on catheter-associated bloodstream infection rates and association with severity of illness. Infect Control Hosp Epidemiol. 2012;33:1268–70.PubMedCrossRef

53.

Lorente L et al. Cost/benefit analysis of chlorhexidine-silver sulfadiazine-impregnated venous catheters for femoral access. Am J Infect Control. 2014;42:1130–2.PubMedCrossRef

54.

Baskin KM et al. Long-term central venous access in pediatric patients at high risk: conventional versus antibiotic-impregnated catheters. J Vasc Interv Radiol. 2014;25:411–8.PubMedCrossRef

55.

Tabak YP, Jarvis WR, Sun X, Crosby CT, Johannes RS. Meta-analysis on central line-associated bloodstream infections associated with a needleless intravenous connector with a new engineering design. Am J Infect Control. 2014;42:1278–84.PubMedCrossRef

56.

Safdar N et al. Chlorhexidine-impregnated dressing for prevention of catheter-related bloodstream infection: a meta-analysis*. Crit Care Med. 2014;42:1703–13.PubMedCentralPubMedCrossRef

57.

Khattak AZ, Ross R, Ngo T, Shoemaker CT. A randomized controlled evaluation of absorption of silver with the use of silver alginate (Algidex) patches in very low birth weight (VLBW) infants with central lines. J Perinatol. 2010;30:337–42.PubMedCrossRef

58.

Hill ML, Baldwin L, Slaughter JC, Walsh WF, Weitkamp J-H. A silver-alginate-coated dressing to reduce peripherally inserted central catheter (PICC) infections in NICU patients: a pilot randomized controlled trial. J Perinatol. 2010;30:469–73.PubMedCrossRef

59.

Institute of Medicine (IOM). Transforming health care quality. (2003). at <http://iom.edu/Reports/2003/Priority-Areas-for-National-Action-Transforming-Health-Care-Quality.aspx> Accessed December 9, 2014.

60.•

Pronovost PJ, Watson SR, Goeschel CA, Hyzy RC, Berenholtz SM. Sustaining reductions in central line-associated bloodstream infections in Michigan intensive care units: a 10-year analysis. Am J Med Qual. 2015. doi:10.1177/1062860614568647. Analysis of data from March 2004 to December 2013 regarding central line associated bloodstream infection rates in ICUs from the Michigan Keystone ICU project, showing long-term sustainability for large-scale improvement projects.

61.

Waters HR et al. The business case for quality: economic analysis of the Michigan Keystone Patient Safety Program in ICUs. Am J Med Qual. 2011;26(5):333–9. doi: 10.1177/1062860611410685.

62.

Lipitz-Snyderman A et al. Impact of a statewide intensive care unit quality improvement initiative on hospital mortality and length of stay: retrospective comparative analysis. BMJ. 2011;342:d219.PubMedCentralPubMedCrossRef

63.

Lin DM, Weeks K, Holzmueller CG, Pronovost PJ, Pham JC. Maintaining and sustaining the On the CUSP: stop BSI model in Hawaii. Jt Comm J Qual Patient Saf. 2013;39:51–60.PubMed

64.

Walz JM et al. The Bundle “Plus”: the effect of a multidisciplinary team approach to eradicate central line-associated bloodstream infections. Anesth Analg. 2013. doi:10.1213/ANE.0b013e3182a8b01b.

65.

Hong AL et al. Decreasing central-line-associated bloodstream infections in Connecticut intensive care units. J Healthc Qual. 2013;35(5):78–87. doi: 10.1111/j.1945-1474.2012.00210.x.

66.

Marsteller JA et al. A multicenter, phased, cluster-randomized controlled trial to reduce central line-associated bloodstream infections in intensive care units*. Crit Care Med. 2012;40:2933–9.PubMedCrossRef

67.

National action plan to prevent healthcare-associated infections: road map to elimination. Department of Health and Human Services web site. 2009. at <http://www.health.gov/hai/prevent_hai.asp> Accessed December 9, 2014.

68.

WHO. Bacteriemia Zero. at <http://www.who.int/patientsafety/implementation/bsi/bacteriemia_zero/en/> Accessed December 9, 2014.

69.

Palomar M et al. Impact of a national multimodal intervention to prevent catheter-related bloodstream infection in the ICU: the Spanish experience. Crit Care Med. 2013;41:2364–72.PubMedCrossRef

70.

Bion J et al. “Matching Michigan”: a 2-year stepped interventional programme to minimise central venous catheter-blood stream infections in intensive care units in England. BMJ Qual Saf. 2012. doi:10.1136/bmjqs-2012-001325.PubMedCentralPubMed

71.

Dixon-Woods M, Leslie M, Tarrant C, Bion J. Explaining Matching Michigan: an ethnographic study of a patient safety program. Implement Sci. 2013;8:70.PubMedCentralPubMedCrossRef

72.

Dixon-Woods M, Leslie M, Bion J, Tarrant C. What counts? An ethnographic study of infection data reported to a patient safety program. Milbank Q. 2012;90:548–91.PubMedCentralPubMedCrossRef

73.••

Blot K, Bergs J, Vogelaers D, Blot S, Vandijck D. Prevention of central line-associated bloodstream infections through quality improvement interventions: a systematic review and meta-analysis. Clin Infect Dis. 2014. doi:10.1093/cid/ciu239. Examination of the impact of quality improvement interventions on central line associated bloodstream infections in adult ICUs, suggesting their beneficial impact, particularly when care bundles and checklists are used.PubMed

74.

Weaver SJ, Weeks K, Pham JC, Pronovost PJ. On the CUSP: Stop BSI: evaluating the relationship between central line-associated bloodstream infection rate and patient safety climate profile. Am J Infect Control. 2014;42:S203–8.PubMedCrossRef

75.

Marsteller JA, Hsu Y-J, Weeks K. Evaluating the impact of mandatory public reporting on participation and performance in a program to reduce central line-associated bloodstream infections: evidence from a national patient safety collaborative. Am J Infect Control. 2014;42:S209–15.PubMedCrossRef

76.

Zingg W et al. Hospital-wide multidisciplinary, multimodal intervention programme to reduce central venous catheter-associated bloodstream infection. PLoS One. 2014;9, e93898.PubMedCentralPubMedCrossRef

77.•

Ziegler MJ, Pellegrini DC, Safdar N. Attributable mortality of central line associated bloodstream infection: systematic review and meta-analysis. Infection. 2014. doi:10.1007/s15010-014-0689-y. Analysis of case control and cohort studies to identify the attributable mortality of central line associated bloodstream infections, demonstrating their association with a significantly increased risk of death.PubMed

78.

Scott RD et al. CDC central-line bloodstream infection prevention efforts produced net benefits of at least $640 Million during 1990–2008. Health Aff (Millwood). 2014;33:1040–7.CrossRef

Title: Eliminating Infections in the ICU: CLABSI
Authors: Asad Latif
Muhammad Sohail Halim
Peter J. Pronovost
Publication date: 01-07-2015
Publisher: Springer US
Published in: Current Infectious Disease Reports / Issue 7/2015
Print ISSN: 1523-3847
Electronic ISSN: 1534-3146
DOI: https://doi.org/10.1007/s11908-015-0491-8

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Eliminating Infections in the ICU: CLABSI

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2015

Empiric Antimicrobial Therapy in Severe Sepsis and Septic Shock: Optimizing Pathogen Clearance

Respiratory Syncytial Virus in Hematopoietic Stem Cell Transplantation and Solid-Organ Transplantation

Transplantation in the Tropics: Lessons on Prevention and Management of Tropical Infectious Diseases

Cutaneous Leishmaniasis in Travellers: a Focus on Epidemiology and Treatment in 2015

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page